Abbott Laboratories’ (NYSE: ABT), despite reporting an excellent second quarter and increasing its full-year guidance, saw its stock price fall by 3.0% this morning.
Robert B. Ford, the CEO of Abbott, believes that the optimism surrounding the company is due to its promising product pipeline. This includes a new over the counter product called Lingo.
Lingo: A potential game-changer
Lingo, Abbott’s popular continuous glucose monitor, is available over-the-counter.
In an interview with CNBC CEO Ford highlighted Lingo’s significant potential, citing a multi-billion dollar opportunity with modest penetration rates and usage rates.
Abbott plans to leverage Libre’s success, which is used daily by more than 6 million people, for Lingo.
The goal is to reach individuals who are not diabetic but would like to learn more about developing healthier habits.
The health care giant expects to launch Lingo within the next few months.
Financial performance and projections
Despite its recent dip, Abbott’s stock is still down about 15% from the high of the year to date in early March.
Ford also emphasized the company’s financial strength and future prospects.
He reiterated Abbott’s commitment to improving the cost profile of its business, with a goal to increase its gross margin this year by 75 basis points.
Abbott raised its full-year guidance because of this potential improvement, as well as a robust product portfolio and strength across all units.
Abbott now expects organic sales growth of up to 9.5%, excluding COVID-19 tests, in 2024. This is an increase from the previous guidance, which was 8.5%.
The company also expects its adjusted earnings per share to range from $4.61 to $4.71 compared to an earlier forecast of $4.55 – $4.70.
Strong Q2 earnings and Analyst Ratings
Abbott Laboratories recently reported a 4.0% growth in annual sales, totaling $10.3 billion, which was in line with analyst expectations. In an interview with CNBC, CEO Ford called these results “pretty amazing”.
Wall Street has a consensus rating of “overweight” for Abbott stock. Analysts project an average gain to $125. This would suggest a 23% increase from current levels. Abbott also offers a dividend yield (2.17%) that makes it more attractive to investors.
Abbott Laboratories could see significant growth in the near future with the launch of Lingo. This innovative product has the potential to capture an important market.
The company’s strong financial results, improved guidance and promising product pipeline makes it a stock worth keeping an eye on, despite the recent stock drop.
This post should you buy Abbott stock. CEO sees multibillion-dollar opportunity in new product. This may change as more information becomes available
This site is for entertainment only. Click here to read more
